Search research articles
Contact Us
Filters
Showing results (51-60 of 56) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 56 results.
NPJ Precision Oncology
|
May 5, 2026
Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis
Binbin Zheng-Lin, Taro Shibuki, Heidi E Kosiorek, et al.
JCO Precision Oncology
|
July 10, 2026
Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers
Priyanshi Shah, Anina Peersen, Vaibhav Sahai, et al.
Hepatology Communications
|
November 16, 2021
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and <sup>68</sup> Ga-PSMA-11 PET Using Cyclotron-Produced <sup>68</sup> Ga
Scott M Thompson, Garima Suman, Michael S Torbenson, et al.
The Oncologist
|
September 19, 2025
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study
Ioannis Kournoutas, Paulina Marell, Jennifer Gile, et al.
Journal of Hepatology
|
July 12, 2024
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis
Mohammad Saeid Rezaee-Zavareh, Yee Hui Yeo, Tielong Wang, et al.
JHEP Reports : Innovation in Hepatology
|
March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab
Simon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 56) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 56 results.
NPJ Precision Oncology
|
May 5, 2026
Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis
Binbin Zheng-Lin, Taro Shibuki, Heidi E Kosiorek, et al.
JCO Precision Oncology
|
July 10, 2026
Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers
Priyanshi Shah, Anina Peersen, Vaibhav Sahai, et al.
Hepatology Communications
|
November 16, 2021
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and <sup>68</sup> Ga-PSMA-11 PET Using Cyclotron-Produced <sup>68</sup> Ga
Scott M Thompson, Garima Suman, Michael S Torbenson, et al.
The Oncologist
|
September 19, 2025
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study
Ioannis Kournoutas, Paulina Marell, Jennifer Gile, et al.
Journal of Hepatology
|
July 12, 2024
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis
Mohammad Saeid Rezaee-Zavareh, Yee Hui Yeo, Tielong Wang, et al.
JHEP Reports : Innovation in Hepatology
|
March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab
Simon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
Page
of 6